Malignant Gastric Neoplasm — Trials

Malignant Gastric Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 650
Recruiting: 355
Ph III recruiting: 49
Growth YoY: +13.6%
Industry share: 26%
Top sponsor: Fudan University
Termination share: 26.1%
Trials / 1,000 deaths: 59.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (232)

clinicaltrialsPublishedShowing 551–600 of 1,056 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05410847	Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells	unknown	Phase 2	30	Hebei Medical UniversityOTHER	0	Jun 24, 2022	clinicaltrials
NCT02447406	Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment	completed	Phase 1 / Phase 2	7	Samsung Medical CenterOTHER